• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director

    12/20/21 1:30:00 AM ET
    $DVAX
    $HARP
    $AMAG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email

    Regulatory News:

    Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director.

    Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion.

    Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where he led its turnaround and strategic sale to Covis Pharma, in November 2020. He has also served as Chairman of the Board and CEO of Rainier Therapeutics, an oncology biotechnology company focused on late-stage bladder cancer treatment, where he led the sale of Vofatamab to Fusion Pharmaceuticals (FUSN). He was previously Chief Executive Officer, President and Director of oncology company Cascadian Therapeutics (CASC) from April 2016 through its acquisition by Seattle Genetics in March 2018. He was also an Independent Director at Trillium Therapeutics (TRIL) until its acquisition by Pfizer (PFE) in September of 2021. In addition to his role at Dynavax and Harpoon, he is currently an Independent Board Director at Selecta Biosciences (SELB). He holds a Bachelor of Arts Degree in Biology from Northwestern University and an M.B.A. from the University of Chicago Booth School of Business.

    Scott will succeed Edwin Moses, who is leaving the Board of Sensorion on December 19 in order to focus on his portfolio of other commitments.

    Nawal Ouzren, CEO of Sensorion, commented: "We are delighted to welcome Scott as our new Chairman. His extensive, world-class experience, spanning research and clinical development, partnering, regulatory and commercialisation, will be key as Sensorion continues to develop its pipeline and international presence. I have known Scott for many years and I look forward to his strategic guidance as we move forward in our journey to make a lasting positive impact for patients around the world with inner ear related disorders.

    "I would like to thank Edwin on behalf of the Board, and personally, for his valued leadership and contributions to Sensorion."

    Scott Myers added: "I am thrilled to be taking on the role of Chairman at this exciting phase of Sensorion's development. I look forward to working with the Board and management to further advance Sensorion's pioneering work to develop novel therapies to restore, treat and prevent hearing loss disorders."

    Edwin Moses commented: "I am proud to have been Chairman of Sensorion. The Company has grown and developed its exciting pipeline of novel therapies for hearing loss disorders. I look forward to watching Sensorion's continued success."

    About Sensorion

    Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion has launched three gene therapy programs, currently at preclinical stage, aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, hearing loss related to gene target GJB2 as well as Usher Syndrome Type 1 to potentially address important hearing loss segments in adults and children. The Company is potentially uniquely placed, through its platforms and pipeline of potential therapeutics, to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders, a significant global unmet medical need.

    www.sensorion.com

    Follow us on Linkedin

    Label: SENSORION

    ISIN: FR0012596468

    Mnemonic: ALSEN

    Disclaimer

    This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2020 annual financial report published on April 9, 2021 and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211219005088/en/

    Get the next $DVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVAX
    $HARP
    $AMAG

    CompanyDatePrice TargetRatingAnalyst
    Dynavax Technologies Corporation
    $DVAX
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    Dynavax Technologies Corporation
    $DVAX
    2/1/2024$20.00Neutral
    Goldman
    Harpoon Therapeutics Inc.
    $HARP
    1/5/2024$23.00Outperform
    Oppenheimer
    Harpoon Therapeutics Inc.
    $HARP
    11/20/2023Outperform
    TD Cowen
    Dynavax Technologies Corporation
    $DVAX
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    Harpoon Therapeutics Inc.
    $HARP
    7/6/2022$16.00Buy
    Canaccord Genuity
    Dynavax Technologies Corporation
    $DVAX
    1/6/2022$38.00Buy
    Goldman
    Dynavax Technologies Corporation
    $DVAX
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    $HARP
    $AMAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dynavax downgraded by Goldman with a new price target

      Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

      2/11/25 7:05:05 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Dynavax with a new price target

      Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

      2/1/24 6:20:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Harpoon Therapeutics with a new price target

      Oppenheimer initiated coverage of Harpoon Therapeutics with a rating of Outperform and set a new price target of $23.00

      1/5/24 8:28:33 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    $HARP
    $AMAG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Silvernail Lauren P was granted 1,439 shares, increasing direct ownership by 17% to 10,075 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:55:43 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kisner Daniel L was granted 5,758 shares, increasing direct ownership by 33% to 23,329 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:53:29 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Myers Scott Dunseth was granted 5,758 shares, increasing direct ownership by 23% to 31,204 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:51:37 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    $HARP
    $AMAG
    SEC Filings

    See more
    • Dynavax Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

      8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/17/25 7:30:35 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Dynavax Technologies Corporation

      DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/9/25 7:44:29 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Dynavax Technologies Corporation

      DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/6/25 6:04:24 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    $HARP
    $AMAG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Merck & Co., Inc. bought $492,135,715 worth of shares (21,397,205 units at $23.00) (SEC Form 4)

      4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)

      3/11/24 3:27:05 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    $HARP
    $AMAG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

      EMERYVILLE, Calif., June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2025 Annual Meeting of Stockholders ("Annual Meeting"), Dynavax stockholders have voted to elect all four of its director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – to the Company's Board of Directors. Dynavax issued the following statement:

      6/11/25 11:01:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

      Deep Track's Nominees Are Prepared to Collectively Enter the Boardroom with Open-Minded Perspectives, Constructive Approach and Sole Focus on Creating Value for All Shareholders Believes that Without Meaningful Board Change "Valid and Critical Questions Regarding Dynavax's Strategic Direction, Capital Allocation, and Board Responsiveness" Will Remain Unanswered Details Urgent Need to Address Company's Consistent Failure to Achieve Stated Targets and Reverse Heplisav Market Share Stagnation Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"),

      6/9/25 8:30:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

      Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Advisory Firms ISS and Egan-Jones and Vote "FOR" All Four of Dynavax's Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., June 9, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement reiterating to stockholders its recommendation to vote "FOR" all four of Dynavax's highly qualified directors standing for e

      6/9/25 7:30:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    $HARP
    $AMAG
    Leadership Updates

    Live Leadership Updates

    See more
    • Deep Track Capital Comments on ISS Recommendation

      Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit

      5/23/25 6:12:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

      ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS

      5/23/25 1:44:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • /C O R R E C T I O N -- Dynavax Technologies/

      In the news release, Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum, issued 07-May-2025 by Dynavax Technologies over PR Newswire, we are advised by the company that the second paragraph, second sentence of the stockholder letter should read "Dynavax has generated over $900 million of stockholder value, returning over 62% versus the S&P Biotechnology Select Industry Index's return of -7%[2]." rather than "Dynavax has generated approximately $1 billion of stockholder value, returning over 104% versus the S&P Biotechnology Select Industry Index's return of only 14%[2]." as originally issued inadvertently. The complete, corre

      5/7/25 4:45:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    $HARP
    $AMAG
    Financials

    Live finance-specific insights

    See more
    • Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

      Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., May 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2025.

      5/6/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

      EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav

      4/22/25 4:00:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

      HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025Top-line results in Phase 1/2 shingles trial expected in Q3 2025Plan to initiate Phase 2 trial for plague vaccine in Q3 2025Expect completion of $200 million share repurchase program in 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Feb. 20, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2024.

      2/20/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    $HARP
    $AMAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Dynavax Technologies Corporation

      SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      11/14/24 12:18:08 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

      SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      10/24/24 4:06:57 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

      SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      10/16/24 9:37:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care